India-based biotech firm Bharat Biotech got regulatory approval to test their coronavirus vaccine on humans, becomes the first indigenous vaccine to enter this stage in the country. The trial is scheduled to start from July across India.
The vaccine was jointly developed by Bharat Biotech and Indian Council of Medical Research’s National Institute of Virology. According to Bharat Biotech in a press release, the company previously submitted pre-clinical studies of the vaccine, demonstrating its immune response and safety.
Bharat Biotech chairman and managing director Dr. Krishna Ella told the Indian Express that the collaboration between the two firms, that is Bharat Biotech and National Institute of Virology was ‘instrumental in the development of this vaccine.’ “We are proud to announce ‘Covaxin’, India’s first indigenous vaccine against Covid-19.”
Other firms engaged in the development of a coronavirus vaccine are Zydus Cadila, Serum Institute of India, and Panacea Biotec. According to WHO, 13 vaccines are in clinical trial phases across the world.
129 are in the pre-clinical evolution phase. AstraZeneca and Johnson & Johnson are two leading candidates in this race of developing a COVID-19 vaccine. J&J